Fundraisings and IPOs

Date: 0000-00-00

Type of information: Private placement

Company: Oasmia Pharmaceutical (Sweden)

Investors:

Amount: SEK 42 million (€ 4.4 million)

Funding type: private placement

Planned used: Oasmia Pharmaceutical intends to use the proceeds from the private placement to strengthen its working capital as well as finance its continuing operations. This financing will give it time to finalize certain ongoing activities which the Board of Directors anticipates will be the basis to fulfil the Company’s long term commercial strategy. Oasmia Pharmaceutical develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications.

Others:  

• • On March 31, 2017, Oasmia Pharmaceutical announced that the company has completed a private placement of a convertible loan in the amount SEK 42,000,193 and placed with a limited group of investors. Oasmia has placed 42 new convertible instruments with a limited group of investors at a nominal value of SEK 1,000,004.60 per convertible instrument through an accelerated book building procedure. The conversion rate is based on the closing price of Oasmia’s shares on Nasdaq Stockholm on 30 March 2017 and will amount to SEK 5.95. The loan matures on 25 April 2017 if not converted to shares, called for by either the convertible holder or the company, or repaid earlier. If the convertible loan is fully converted into shares, the number of shares in Oasmia increases by 7,058,856 from 119,039,310 to 126,098,166 and the share capital increases by SEK 705,886 from SEK 11,903,931 to SEK 12,609,817. In the event of a full conversion into shares, the dilution effect will amount to approximately 5.6 per cent.

Therapeutic area: Cancer - Oncology - Veterinary medicine

Is general: Yes